Announcements Trials
Browse Landscape

Phase

Phase 3 12Phase 2 8Phase 4 5Phase NA 3Phase 2/3 2Phase 1/2 2Phase 1 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1CNS 1

Conditions

Head and Neck Neoplasms 1Glioblastoma 1Epilepsy 1

Interventions

pembrolizumab 410Cyclophosphamide 394Carboplatin 306Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 210Bevacizumab 209fludarabine 192Docetaxel 187Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 120Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Gabapentin × Clear all
NCT05156060 2024-10-21

Gabapentin & Ketamine for Prevention/Treatment of Acute/Chronic Pain in Locally Advanced Head and Neck Cancer

Vanderbilt-Ingram Cancer Center

Phase 1/2 Recruiting
64 enrolled
Head & Neck

Head and Neck Neoplasms

NCT05664464 2024-05-10

GLUGLIO

University of Zurich

Phase 1/2 Recruiting
120 enrolled
CNS

Epilepsy, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡